MGEN - Miragen Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7001
-0.0499 (-6.65%)
At close: 4:00PM EST

0.7110 +0.01 (1.56%)
Pre-Market: 8:27AM EST

Stock chart is not supported by your current browser
Previous Close0.7500
Open0.7400
Bid0.0000 x 3000
Ask0.0000 x 800
Day's Range0.6901 - 0.7423
52 Week Range0.4400 - 3.8000
Volume2,932,467
Avg. Volume2,486,316
Market Cap24.407M
Beta (5Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)-1.3590
Earnings DateNov 06, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.40
  • Has Signal Genetics (MGEN) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Signal Genetics (MGEN) Outpaced Other Medical Stocks This Year?

    Is (MGEN) Outperforming Other Medical Stocks This Year?

  • GlobeNewswire

    miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock

    BOULDER, Colo., Feb. 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and warrants to purchase up to an aggregate of 7,500,000 shares of its common stock. Each share of common stock is being sold together with one-half warrant, with each whole warrant exercisable to purchase one whole share of common stock. Each share of common stock and accompanying one-half warrant is being sold for a combined purchase price of $1.00, for a gross deal size of $15.0 million, not including any future proceeds from the exercise of the warrants and before deducting the underwriting discounts and commissions and offering expenses.

  • GlobeNewswire

    miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

    BOULDER, Colo., Feb. 06, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it intends to offer for sale shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. All of the common stock and warrants to purchase common stock are being offered by miRagen. This offering is being made pursuant to an effective shelf registration statement of miRagen filed with the Securities and Exchange Commission (the SEC).

  • Company News for Jan 31, 2020
    Zacks

    Company News for Jan 31, 2020

    Companies In The News Are: BGG, INO, MDLZ, MGEN

  • GlobeNewswire

    miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease

    BOULDER, Colo., Jan. 30, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced new efficacy and safety data from the ATLL arm of its ongoing Phase 1 clinical trial of cobomarsen, which will be presented at the 12th Annual T-Cell Lymphoma Forum in La Jolla, CA, which is taking place from January 30th to February 1st. Of note are the data from the subtype of aggressive ATLL patients who at study entry had persistent residual disease after chemotherapy or other therapy. The Company was most encouraged, however, by the observed biomarker activity showing that disease stabilization is marked by a decrease in biomarkers of tumor cells activation and proliferation, providing evidence of the biological mechanism effect of cobomarsen on disease stabilization.

  • GlobeNewswire

    miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences

    BOULDER, Colo., Jan. 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that it will present new efficacy and safety data from its Phase 1 trial of cobomarsen in adult T-cell leukemia/lymphoma (ATLL) at the 12th Annual T-Cell Lymphoma Forum, which is being held in La Jolla, CA, from January 30th to February 1st.

  • Benzinga

    The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: ...

  • Benzinga

    The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

  • GlobeNewswire

    miRagen Announces Major Changes to Company’s Strategy

    BOULDER, Colo., Dec. 11, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced a series of strategic changes across its business that are intended to reallocate its existing capital to deliver important milestones in 2020.

  • GlobeNewswire

    miRagen to Present at the Evercore ISI HealthCONx Conference 2019

    BOULDER, Colo., Nov. 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that management will be presenting at the Evercore ISI HealthCONx Conference 2019 on Tuesday, December  3rd,  taking place at the Four Seasons Hotel in Boston, Massachusetts.

  • Could Miragen Therapeutics, Inc.'s (NASDAQ:MGEN) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Miragen Therapeutics, Inc.'s (NASDAQ:MGEN) Investor Composition Influence The Stock Price?

    A look at the shareholders of Miragen Therapeutics, Inc. (NASDAQ:MGEN) can tell us which group is most powerful...

  • Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Lags Revenue Estimates
    Zacks

    Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Lags Revenue Estimates

    Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -20.00% and -58.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    miRagen Reports Third Quarter 2019 Results and Provides Corporate Update

    BOULDER, Colo., Nov. 07, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the third quarter ended September 30, 2019 and provided a corporate update. “The miRagen team continues to generate clinical data essential to advancing our portfolio of microRNA targeting therapies being developed to address a number of complex diseases. “We recently released data from two Phase 1 clinical trials in which MRG-110, one of our three clinical stage product candidates, was observed to positively impact tissue repair and new blood vessel growth in humans.

  • Earnings Preview: Signal Genetics, Inc. (MGEN) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: Signal Genetics, Inc. (MGEN) Q3 Earnings Expected to Decline

    Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference Today

    An overview of its second-generation miR-29 mimicsClinical development of its microRNA inhibitors BOULDER, Colo., Oct. 28, 2019 -- miRagen Therapeutics, Inc. (NASDAQ: MGEN),.

  • GlobeNewswire

    miRagen Therapeutics to Report Third Quarter 2019 Financial Results and Host a Conference Call

    BOULDER, Colo., Oct. 22, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will host a conference call and webcast on Thursday, November 7th, at 4:30 p.m. ET to discuss a corporate update and results for the third quarter of 2019. A live webcast can be accessed from the Investors and Media section of the miRagen Therapeutics website. A replay of this conference call will be available on miRagen’s website approximately one hour after the event.

  • GlobeNewswire

    miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth

    BOULDER, Colo., Oct. 16, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today new data from two Phase 1 clinical trials of MRG-110, miRagen’s microRNA-92 inhibitor, in which administration of MRG-110 was observed to increase angiogenesis, as demonstrated by increased perfusion and histological markers of neoangiogenesis, as well as reduce alpha-smooth muscle actin (α-SMA) expression, which has been show to correlate with activation of myofibroblasts. “We believe these Phase 1 safety, tolerability, pharmacokinetics, and biomarker data may provide mechanistic proof-of-concept for use of MRG-110 in the treatment of cardiovascular disease and certain other conditions where vascular flow is compromised,” said Paul Rubin, M.D., Executive Vice President, R&D, of miRagen Therapeutics.

  • GlobeNewswire

    miRagen Therapeutics to Present a Corporate Overview at the Robert W. Baird & Co. 2019 Global Healthcare Conference

    BOULDER, Colo., Aug. 15, 2019 -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a.

  • GlobeNewswire

    miRagen Therapeutics to Present a Corporate Overview at the 2019 Wedbush Healthcare Conference

    BOULDER, Colo., Aug. 12, 2019 -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a.

  • Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Tops Revenue Estimates

    Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 21.62% and 184.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    miRagen Reports Second Quarter 2019 Results; Regains Global Rights to MRG-110 and Announces Corporate Restructuring

    BOULDER, Colo., Aug. 07, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the second quarter ended June 30, 2019 and provided a corporate update.

  • Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out for

    Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Miragen Therapeutics to Report Second Quarter 2019 Financial Results and Host a Conference Call on August 7th

    BOULDER, Colo., July 24, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will host a conference call on Wednesday, August 7th, at 4:30 p.m. ET to discuss its financial results for the second quarter and six months ended June 30, 2019. The call will also be webcast and can be accessed from the Investors and Media section of the Company’s website at www.miragen.com.  A replay of this conference call will be available on miRagen’s website approximately one hour after the event.

  • Some Miragen Therapeutics (NASDAQ:MGEN) Shareholders Have Copped A Big 66% Share Price Drop
    Simply Wall St.

    Some Miragen Therapeutics (NASDAQ:MGEN) Shareholders Have Copped A Big 66% Share Price Drop

    The nature of investing is that you win some, and you lose some. And there's no doubt that Miragen Therapeutics, Inc...

  • GlobeNewswire

    miRagen Therapeutics to Present a Corporate Overview at the Jefferies 2019 Global Healthcare Conference

    BOULDER, Colo., May 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Jefferies 2019 Global Healthcare Conference, taking place June 4-7 in New York City.